
REVISTA MEDICINA LEGAL DE COSTA RICA ISSN 2215 -5287 Vol. 37 (1) Marzo 2020
17- Miller N, Walsh F, Hoyt W. Walsh and Hoyt's clinical neuro-ophthalmology. Philadelphia:
Lippincott Williams & Wilkins; 2005.
18- Gutman I, Levartovski S, Goldhammer Y, Tadmor R, Findler G. Sixth Nerve Palsy and Unilateral
Horner's Syndrome. Ophthalmology. 1986;93(7):913-916.
19- Maloney W, Younge B, Moyer N. Evaluation of the Causes and Accuracy of Pharmacologic
Localization in Horner's Syndrome. American Journal of Ophthalmology. 1980;90(3):394-402.
20- Najem K, Margolin E. A Special Case of Horner Syndrome. JAMA Ophthalmology.
2016;134(10):1193.
21- Pearce J. Wallenberg's syndrome. Journal of Neurology, Neurosurgery & Psychiatry.
2000;68(5):570-570.
22- Biousse V, Guevara R, Newman N. Transient Horner's syndrome after lumbar epidural anesthesia.
Neurology. 1998;51(5):1473-1475.
23- Perry C, James D, Wixon C, Mills J, Ericksen C. Horner's Syndrome After Carotid Endarterectomy.
Vascular Surgery. 2001;35(4):325-327.
24- Fujisawa H, Marukawa K, Kida S, Hasegawa M, Yamashita J, Matsui a. Abducens Nerve Palsy and
Ipsilateral Horner Syndrome: A Predicting Sign of Intracranial Carotid Injury in a Head Trauma
Patient. The Journal of Trauma: Injury, Infection, and Critical Care. 2001;50(3):554-556.
25- Thompson HS, Miller NR. Disorders of pupillary function, accommodation and lacrimation. In:
Miller NR, Newman NJ, eds. Walsh and Hoyt’s clinical neuro-ophthalmology, 5th edn, vol 1.
Baltimore: Williams & Wilkins, 1998: 961–1040.
26- Morrison D, Bibby K, Woodruff G. The "harlequin" sign and congenital Horner's syndrome. Journal
of Neurology, Neurosurgery & Psychiatry. 1997;62(6):626-628.
27- Kardon R. Are we ready to replace cocaine with apraclonidine in the pharmacologic diagnosis of
Horner syndrome? J Neurophthalmol 2005; 25: 69-79. 2. Ophthalmol.1990;110(1):71–76.
28- Kardon RH , DenisonCE, BrownCK, ThompsonHS. Critical evaluation of the cocaine test in the
diagnosis of Horner’s syndrome.Arch Ophthalmol.1990;108(12):384–387.
29- Morales J, Brown SM, Abdul-Rahim AS, Crosson CE. Ocular effects of apraclonidine in Horner
syndrome. Arch Ophthalmol 2000; 118: 951-954.
30- Brown SM, Aouchiche R, Freedman KA. The utility of 0.5% apraclonidine in the diagnosis of
Horner syndrome. Arch Ophthalmol 2003; 121: 1201-1203.
31- Mahoney NR , LiuGT, MenackerSJ, WilsonMC, HogartyMD, MarisJM. Pediatric Horner
syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other
responsible mass lesions.Am J Ophthalmol.2006;142(4):651–659.
32- Koc F. The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic
paresis. British Journal of Ophthalmology. 2005;89(11):1442-1444.
33- Kanagalingam S, Miller NR. Horner syndrome: Clinical perspectives. Eye and Brain. 2015 Apr
10;7:35-46.
34- Waqar S, McMurray C, Madge S. Transcutaneous Blepharoptosis Surgery - Advancement of
Levator Aponeurosis. The Open Ophthalmology Journal. 2010;4(1):76-80.
35- Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S. Effect of 0.5% Apraclonidine on Ptosis in
Horner Syndrome. Ophthalmic Plastic & Reconstructive Surgery. 2006;22(1):53-55.